nordicMEDiVA

The nordicMEDiVA is an advanced software platform designed for the visualization and processing of functional and dynamic MRI data of the human brain. It operates as a server-client solution, presenting derived neuroimaging properties and parameters to qualified medical personnel, validated through non-clinical performance and usability testing to be substantially equivalent to predicate devices for clinical utility.

On October 22, 2024, the U.S. Food & Drug Administration informed NordicNeurolab AS, represented by Prithul Bom, that their device, nordicMEDiVA, has been determined to be substantially equivalent to legally marketed predicate devices. This determination allows NordicNeurolab AS to market the device, a Class II product identified by regulation number 21 CFR 892.2050 (Medical image management and processing system). The device is subject to general controls, including requirements for annual registration, device listing, good manufacturing practices, and proper labeling. The nordicMEDiVA software is an advanced visualization and processing platform designed to analyze functional and dynamic MRI data of the brain. It operates as a server-client solution, accessible via a web browser, and is intended for use by qualified medical personnel, such as trained radiological technicians or physicians, with expertise in MR technology and neuroanatomy. The software is indicated for image analysis and visualization, presenting derived properties and parameters in a clinically useful context, but it is not intended for patient image data archiving, as a sole basis for clinical decisions or emergency care, or for applications other than human brain MR data analysis. The manufacturer must comply with ongoing regulatory requirements, including quality system regulations, unique device identification, and adverse event reporting. Non-clinical performance testing and usability studies confirmed the device's compliance with standards and its effectiveness compared to predicate devices.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific algorithms or processing techniques does nordicMEDiVA employ for analyzing functional and dynamic MRI data?; How do the derived properties and parameters presented by nordicMEDiVA aid in clinical decision-making, despite not being a sole basis for diagnosis?; What are the quantitative performance metrics from the non-clinical testing and usability studies that demonstrate nordicMEDiVA's equivalence to predicate devices?; Are there any plans for nordicMEDiVA to expand its capabilities beyond human brain MR data analysis to other body regions or imaging modalities?; What kind of training or certification is required for medical personnel to effectively use nordicMEDiVA, given its specialized application in neuroimaging?